Plasma C-type lectin-like receptor 2 as a predictor of death and vascular events in patients with acute ischemic stroke

被引:22
作者
Wu, X. [1 ]
Zhang, W. [1 ]
Li, H. [2 ]
You, S. [1 ]
Shi, J. [1 ]
Zhang, C. [1 ]
Shi, R. [1 ]
Huang, Z. [1 ]
Cao, Y. [1 ]
Zhang, X. [1 ]
机构
[1] Soochow Univ, Dept Neurol, Affiliated Hosp 2, 1055 Sanxiang Rd, Suzhou 215004, Peoples R China
[2] Soochow Univ, Dept Cardiol, Affiliated Hosp 2, Suzhou, Peoples R China
基金
中国国家自然科学基金;
关键词
acute ischaemic stroke; death; pCLEC-2; prognostic; vascular diseases; GLYCOPROTEIN-VI; ARTERIAL THROMBOSIS; INFLAMMATION; EXPRESSION; CLEC-2; GPVI; MICE;
D O I
10.1111/ene.13984
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background and purpose C-type lectin-like receptor 2 (CLEC-2) has prominent involvement in platelet activation, which is increased in coronary heart disease and acute ischaemic stroke (AIS) and is associated with stroke progression and stroke prognosis. Here, the aim was to examine the prognostic value of CLEC-2 in death and vascular event recurrence in AIS patients. Methods In all, 352 patients with AIS were studied prospectively. All patients were followed up for 1 year. Death for all vascular events and a combination of death and vascular diseases (recurrent stroke, myocardial infarction, hospitalized and treated angina, hospitalized and treated peripheral arterial disease) were recorded. Results During 1 year of follow-up, 46 patients (14.2%) experienced death or combined end-points (23 death and 46 combined end-points). Plasma CLEC-2 (pCLEC-2) was significantly associated with an increased risk of death and combined events of death and vascular diseases after adjusting for age, sex, history of hypertension, diabetes mellitus and coronary artery disease, and National Institutes of Health Stroke Scale scores. Each 1 SD higher log-transformed pCLEC-2 was associated with a 4.27-fold (hazard ratio 4.27, 95% confidence interval 1.71-10.65) increased risk for death and a 2.42-fold increased risk for combined end-points (hazard ratio 2.42, 95% confidence interval 1.52-3.86). The optimal cut-off point of pCLEC-2 for predicting death was 184.38 pg/ml. Conclusions Higher pCLEC-2 levels at admission were associated with increased risk of death and combined events of death and vascular diseases in patients with AIS, which indicated that pCLEC-2 is an important prognostic factor for AIS.
引用
收藏
页码:1334 / 1340
页数:7
相关论文
共 23 条
  • [1] Soluble Glycoprotein VI Is Raised in the Plasma of Patients With Acute Ischemic Stroke
    Al-Tamimi, Mohammad
    Gardiner, Elizabeth E.
    Thom, Jim Y.
    Shen, Yang
    Cooper, Matthew N.
    Hankey, Graeme J.
    Berndt, Michael C.
    Baker, Ross I.
    Andrews, Robert K.
    [J]. STROKE, 2011, 42 (02) : 498 - 500
  • [2] Combined In Vivo Depletion of Glycoprotein VI and C-Type Lectin-Like Receptor 2 Severely Compromises Hemostasis and Abrogates Arterial Thrombosis in Mice
    Bender, Markus
    May, Frauke
    Lorenz, Viola
    Thielmann, Ina
    Hagedorn, Ina
    Finney, Brenda A.
    Voegtle, Timo
    Remer, Katharina
    Braun, Attila
    Boesl, Michael
    Watson, Steve P.
    Nieswandt, Bernhard
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2013, 33 (05) : 926 - U146
  • [3] Glycoprotein VI as a prognostic biomarker for cardiovascular death in patients with symptomatic coronary artery disease
    Bigalke, Boris
    Stellos, Konstantinos
    Geisler, Tobias
    Lindemann, Stephan
    May, Andreas E.
    Gawaz, Meinrad
    [J]. CLINICAL RESEARCH IN CARDIOLOGY, 2010, 99 (04) : 227 - 233
  • [4] Thromboinflammation in Stroke Brain Damage
    De Meyer, Simon F.
    Denorme, Frederik
    Langhauser, Friederike
    Geuss, Eva
    Fluri, Felix
    Kleinschnitz, Christoph
    [J]. STROKE, 2016, 47 (04) : 1165 - 1172
  • [5] Fei M, 2016, THESISL SOOCHOW U
  • [6] The GPVI-Fc Fusion Protein Revacept Improves Cerebral Infarct Volume and Functional Outcome in Stroke
    Goebel, Silvia
    Li, Zhongmin
    Vogelmann, Jasmin
    Holthoff, Hans-Peter
    Degen, Heidrun
    Hermann, Dirk M.
    Gawaz, Meinrad
    Ungerer, Martin
    Muench, Goetz
    [J]. PLOS ONE, 2013, 8 (07):
  • [7] Podoplanin expression in advanced atherosclerotic lesions of human aortas
    Hatakeyama, Kinta
    Kaneko, Mika Kato
    Kato, Yukinari
    Ishikawa, Tetsunori
    Nishihira, Kensaku
    Tsujimoto, Yuta
    Shibata, Yoshisato
    Ozaki, Yukio
    Asada, Yujiro
    [J]. THROMBOSIS RESEARCH, 2012, 129 (04) : E70 - E76
  • [8] Inflammation drives thrombosis after Salmonella infection via CLEC-2 on platelets
    Hitchcock, Jessica R.
    Cook, Charlotte N.
    Bobat, Saeeda
    Ross, Ewan A.
    Flores-Langarica, Adriana
    Lowe, Kate L.
    Khan, Mahmood
    Dominguez-Medina, C. Coral
    Lax, Sian
    Carvalho-Gaspar, Manuela
    Hubscher, Stefan
    Rainger, G. Ed
    Cobbold, Mark
    Buckley, Christopher D.
    Mitchell, Tim J.
    Mitchell, Andrea
    Jones, Nick D.
    Van Rooijen, N.
    Kirchhofer, Daniel
    Henderson, Ian R.
    Adams, David H.
    Watson, Steve P.
    Cunningham, Adam F.
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2015, 125 (12) : 4429 - 4446
  • [9] Vascular Smooth Muscle Cells Stimulate Platelets and Facilitate Thrombus Formation through Platelet CLEC-2: Implications in Atherothrombosis
    Inoue, Osamu
    Hokamura, Kazuya
    Shirai, Toshiaki
    Osada, Makoto
    Tsukiji, Nagaharu
    Hatakeyama, Kinta
    Umemura, Kazuo
    Asada, Yujiro
    Suzuki-Inoue, Katsue
    Ozaki, Yukio
    [J]. PLOS ONE, 2015, 10 (09):
  • [10] New advances in treating thrombotic diseases: GPVI as a platelet drug target
    Jiang, Peng
    Jandrot-Perrus, Martine
    [J]. DRUG DISCOVERY TODAY, 2014, 19 (09) : 1471 - 1475